12.07.2015 Views

ION Informs Special Announcement: Amgen Contract Update

ION Informs Special Announcement: Amgen Contract Update

ION Informs Special Announcement: Amgen Contract Update

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

http://view.ipnonline-email.com/?j=fe5d1677726705797217&m=ff021071716705&ls=fde...Page 1 of 22/17/2010To view this email as a web page, go here.<strong>ION</strong>'s <strong>Announcement</strong>s for 2-16-2010<strong>Amgen</strong> <strong>Contract</strong> <strong>Update</strong><strong>Amgen</strong> and <strong>ION</strong> have extended their contractual agreement,which brings <strong>ION</strong> members discounts and/or rebates onNeulasta® (pegfilgrastim) and Neupogen® (filgrastim),through March 31, 2011. As part of the contract extension,several amendments affecting the percentage of rebates anddiscounts received will take effect on April 1, 2010.As of April 1, 2010, wholesale acquisition cost (WAC)discounts on purchases of Neulasta will increase from 15%to 18%, while quarterly rebate percentages will decrease.Actual rebate rates will be determined and affected based oneach practice's individual program qualifications.WAC discounts on vials and Singleject formations ofNeupogen will also decrease.If you have any questions about this, or any other contract,please contact your <strong>ION</strong> strategic account manager. Todetermine your practice's specific pricing, please contactOncology Supply customer service, or log in towww.oncologysupply.com.Regulations governing the Federalhealth care programs require you toprovide information related to any pricereductions you receive, includingdiscounts and/or rebates, on items thatare reimbursed by Medicare and/orMedicaid to governmental agenciesupon request. In addition, dependingon the type of health care provider youare, you may be required to report anyprice concessions you receive on costreports filed to any such Programsseeking reimbursement. Please notethat you are required to retain allinformation related to the pricereduction addressed in thiscommunication, and that you mustprovide this information to governmentagencies in the event they request itfrom you.<strong>ION</strong> Publications• See the Winter 2009OncologisticsmagazineNeulasta and Neupogen should only be used in clinicallyappropriate situations based on their indications. It isimportant to note that we are providing you the informationabove about the status of our negotiated pricing arrangementfor informational purposes only. You should exercise yourindependent professional judgment related to the usage ofthese and any other product.This email was sent to: corrie.lockhart@iononline.comThis email was sent by: <strong>ION</strong>, An AmerisourceBergen <strong>Special</strong>ty Group Company3101 Gaylord Parkway Frisco, TX 75034 USA


http://view.ipnonline-email.com/?j=fe5d1677726705797217&m=ff021071716705&ls=fde...Page 2 of 22/17/2010We respect your right to privacy - view our policyThis communication is intended to keep <strong>ION</strong> members current on late breaking events. It may contain confidentialinformation such as pricing, rebate, and other discount arrangements being provided exclusively to <strong>ION</strong> members,and as such is intended solely for the use of the addressee. If the reader of this message is not the intendedrecipient, you are hereby notified that any dissemination, copying, distribution or other use of this material is strictlyprohibited. In the event that you have received this material in error, or wish to opt-out of any future emails, pleaseGo Here or notify the sender immediately via email or telephone at 866-565-1070 and destroy all copies. Thank you.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!